- The role of different viral biomarkers on the management of chronic hepatitis B
-
Mak LY, Hui RWH, Fung J, Seto WK, Yuen MF
- KMID: 2541405
- Clin Mol Hepatol.
- 2023 Apr;29(2):263-276.
- doi: 10.3350/cmh.2022.0448
Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess... -
- CITED
-
- Close
- SHARE
-
- Close
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
-
Hui RWH, Mak LY, Seto WK, Yuen MF
- KMID: 2531368
- Clin Mol Hepatol.
- 2022 Jul;28(3):408-424.
- doi: 10.3350/cmh.2022.0012
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective
-
Hui RWH, Mak LY, Cheung TT, Lee VHF, Seto WK, Yuen MF
- KMID: 2541401
- Clin Mol Hepatol.
- 2023 Apr;29(2):217-229.
- doi: 10.3350/cmh.2022.0399
Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
-
Cheung KS, Lam LK, Hui RWH, Mao X, Zhang RR, Chan KH, Hung IF, Seto WK, Yuen MF
- KMID: 2531378
- Clin Mol Hepatol.
- 2022 Jul;28(3):553-564.
- doi: 10.3350/cmh.2022.0082
Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred... -
- CITED
-
- Close
- SHARE
-
- Close
